Setting the new FRAX reference threshold without bone mineral density in Chinese postmenopausal women.


Journal

Journal of endocrinological investigation
ISSN: 1720-8386
Titre abrégé: J Endocrinol Invest
Pays: Italy
ID NLM: 7806594

Informations de publication

Date de publication:
Feb 2021
Historique:
received: 30 03 2020
accepted: 27 05 2020
pubmed: 5 6 2020
medline: 12 10 2021
entrez: 5 6 2020
Statut: ppublish

Résumé

Despite the large number of osteoporosis patients in China, the diagnosis and treatment rates remain low. The Fracture Risk Assessment Tool (FRAX) can be used to effectively evaluate fracture risk. In this study, we explored the Chinese-specific thresholds of FRAX without the T-score. In all, 264 postmenopausal women aged > 50 years were randomly recruited from community-medical centers. All subjects completed self-reported questionnaires, BMD measurements, and spinal radiographs. The 10-year hip and major osteoporotic fracture risks were calculated by FRAX. A new threshold for both 10-year hip and major osteoporotic fracture risk was explored with receiver operating characteristic (ROC) curve analysis. Overall, 92 subjects were diagnosed with osteoporosis. Among them, 14 participants with T-score > - 2.5 were diagnosed with osteoporosis based on clinical fractures. ROC analysis showed the cut-off value of the 10-year hip osteoporotic fracture for detecting osteoporosis was 0.95%, while that of 10-year major osteoporotic fracture was 4.95%. The sensitivity and specificity of the 10-year hip osteoporotic fracture probability for detecting osteoporosis were 0.86 and 0.59, respectively, while the guideline-recommended threshold had a sensitivity of 0.49 and specificity of 0.83. The sensitivity and specificity of the 10-year major osteoporotic fractures with the new threshold were 0.76 and 0.69, respectively, while the recommended threshold had a sensitivity of 0 and specificity of 1. Current guideline-recommended FRAX thresholds without BMD showed low sensitivity. Therefore, 10-year osteoporotic hip fracture probability ≥ 0.95% and 10-year osteoporotic major fracture probability ≥ 4.95% are recommended as the new thresholds.

Identifiants

pubmed: 32495298
doi: 10.1007/s40618-020-01315-4
pii: 10.1007/s40618-020-01315-4
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

347-352

Subventions

Organisme : National Natural Science Foundation of China
ID : 81471091
Organisme : National Natural Science Foundation of China
ID : 81870622
Organisme : Hunan Nature Science Foundation
ID : 2019JJ2574
Organisme : Bethune Charitable Foundation
ID : G-X-2019-1107-3

Références

NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy (2001) Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785–795
doi: 10.1001/jama.285.6.785
Black DM, Rosen CJ (2016) Clinical practice. Postmenopausal Osteoporosis N Engl J Med 374:254–262
doi: 10.1056/NEJMcp1513724
Si L, Winzenberg TM, Jiang Q et al (2015) Projection of osteoporosis-related fractures and costs in China: 2010–2050. Osteoporos Int 26:1929–1937
doi: 10.1007/s00198-015-3093-2
Melton LJ III, Chrischilles EA, Cooper C et al (2005) How many women have osteoporosis? JBMR anniversary classic. JBMR, volume 7, number 9, 1992. J Bone Miner Res 20:886–892
doi: 10.1359/jbmr.2005.20.5.886
US Preventive Services Task Force, Curry SJ, Krist AH et al (2018) Screening for osteoporosis to prevent fractures: US preventive services task force recommendation statement. JAMA 319:2521–2531
doi: 10.1001/jama.2018.7498
Kanis JA (2008) on behalf of the World Health Organization Scientific Group 2008b Assessment of osteoporosis at the primary healthcare level. Technical Report. WHO Collaborating Centre, University of Sheffield, UK. https://www.sheffield.ac.uk/FRAX/pdfs/WHO_Technical_Report.pdf . Accessed 12 May 2018
Cosman F, de Beur SJ, LeBoff MS et al (2014) Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int 25:2359–2381
doi: 10.1007/s00198-014-2794-2
Chinese Society of Osteoporosis and Bone Mineral Research (2017) Guidelines for the diagnosis and management of primary osteoporosis. Chin J Osteoporos Bone Miner Res 10:413–444. https://doi.org/10.3969/j.issn.1674-2591.2017.05.002
doi: 10.3969/j.issn.1674-2591.2017.05.002
Compston J, Cooper A, Cooper C et al (2017) UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos 12:43
doi: 10.1007/s11657-017-0324-5
Liu SY, Huang M, Chen R et al (2019) Comparison of strategies for setting intervention thresholds for Chinese postmenopausal women using the FRAX model. Endocrine 65:200–206
doi: 10.1007/s12020-019-01951-8
Wang O, Hu Y, Gong S et al (2015) A survey of outcomes and management of patients post fragility fractures in China. Osteoporos Int 26:2631–2640
doi: 10.1007/s00198-015-3162-6
Sheng Z, Xu K, Ou Y et al (2011) Relationship of body composition with prevalence of osteoporosis in central south Chinese postmenopausal women. Clin Endocrinol (Oxf) 74:319–324
doi: 10.1111/j.1365-2265.2010.03941.x
Genant HK, Wu CY, van Kuijk C et al (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137–1148
doi: 10.1002/jbmr.5650080915
Grados F, Roux C, de Vernejoul MC et al (2001) Comparison of four morphometric definitions and a semiquantitative consensus reading for assessing prevalent vertebral fractures. Osteoporos Int 12:716–722
doi: 10.1007/s001980170046
Xia WB, He SL, Xu L et al (2012) Rapidly increasing rates of hip fracture in Beijing, China. J Bone Miner Res 27:125–129
doi: 10.1002/jbmr.519
Tian FM, Zhang L, Zhao HY et al (2014) An increase in the incidence of hip fractures in Tangshan, China. Osteoporos Int 25:1321–1325
doi: 10.1007/s00198-013-2600-6
WHO Study Group (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 843:1–129
Kim JW, Koh JM, Park JH et al (2015) Validation of FRAX without BMD: an age-related analysis of the Fifth Korean National Health and Nutrition Examination Survey (KNHANES V-1, 2010). Bone 75:27–31
doi: 10.1016/j.bone.2015.02.013
Oka R, Ohira M, Suzuki S et al (2018) Fracture risk assessment tool (FRAX) and for the diagnosis of osteoporosis in Japanese middle-aged and elderly women: Chiba bone survey. Endocr J 65:193–202
doi: 10.1507/endocrj.EJ17-0331
Chen XF, Li XL, Zhang H et al (2014) Were you identified to be at high fracture risk by FRAX(R) before your osteoporotic fracture occurred? Clin Rheumatol 33:693–698
doi: 10.1007/s10067-014-2533-2
Xu J, Sun M, Wang Z et al (2013) Awareness of osteoporosis and its relationship with calcaneus quantitative ultrasound in a large Chinese community population. Clin Interv Aging 8:789–796
pubmed: 23836969 pmcid: 3699130

Auteurs

S Liu (S)

Department of Metabolism and Endocrinology, The 2nd Xiangya Hospital, Central South University, 139 Renmin Road, Changsha, 410011, Hunan, People's Republic of China.
National Clinical Research Center for Metabolic Diseases, The 2nd Xiangya Hospital, Central South University, 139 Renmin Road, Changsha, 410011, Hunan, People's Republic of China.
Health Management Center, The 2nd Xiangya Hospital, Central South University, 139 Renmin Road, Changsha, 410011, Hunan, People's Republic of China.
Hunan Provincial Key Laboratory of Metabolic Bone Diseases, The 2nd Xiangya Hospital, Central South University, 139 Renmin Road, Changsha, 410011, Hunan, People's Republic of China.

R Chen (R)

Department of Metabolism and Endocrinology, The 2nd Xiangya Hospital, Central South University, 139 Renmin Road, Changsha, 410011, Hunan, People's Republic of China.
National Clinical Research Center for Metabolic Diseases, The 2nd Xiangya Hospital, Central South University, 139 Renmin Road, Changsha, 410011, Hunan, People's Republic of China.
Health Management Center, The 2nd Xiangya Hospital, Central South University, 139 Renmin Road, Changsha, 410011, Hunan, People's Republic of China.
Hunan Provincial Key Laboratory of Metabolic Bone Diseases, The 2nd Xiangya Hospital, Central South University, 139 Renmin Road, Changsha, 410011, Hunan, People's Republic of China.
Department of Metabolism and Endocrinology, The Affiliated Zhuzhou Hospital Of XiangYa School Of Medicine, Central South University, Changjiang South Road116, Zhuzhou, 412007, Hunan, People's Republic of China.

N Ding (N)

Department of Metabolism and Endocrinology, The 2nd Xiangya Hospital, Central South University, 139 Renmin Road, Changsha, 410011, Hunan, People's Republic of China.
National Clinical Research Center for Metabolic Diseases, The 2nd Xiangya Hospital, Central South University, 139 Renmin Road, Changsha, 410011, Hunan, People's Republic of China.
Health Management Center, The 2nd Xiangya Hospital, Central South University, 139 Renmin Road, Changsha, 410011, Hunan, People's Republic of China.
Hunan Provincial Key Laboratory of Metabolic Bone Diseases, The 2nd Xiangya Hospital, Central South University, 139 Renmin Road, Changsha, 410011, Hunan, People's Republic of China.

Q Wang (Q)

Department of Metabolism and Endocrinology, The 2nd Xiangya Hospital, Central South University, 139 Renmin Road, Changsha, 410011, Hunan, People's Republic of China.
National Clinical Research Center for Metabolic Diseases, The 2nd Xiangya Hospital, Central South University, 139 Renmin Road, Changsha, 410011, Hunan, People's Republic of China.
Health Management Center, The 2nd Xiangya Hospital, Central South University, 139 Renmin Road, Changsha, 410011, Hunan, People's Republic of China.
Hunan Provincial Key Laboratory of Metabolic Bone Diseases, The 2nd Xiangya Hospital, Central South University, 139 Renmin Road, Changsha, 410011, Hunan, People's Republic of China.

M Huang (M)

Department of Metabolism and Endocrinology, The 2nd Xiangya Hospital, Central South University, 139 Renmin Road, Changsha, 410011, Hunan, People's Republic of China.
National Clinical Research Center for Metabolic Diseases, The 2nd Xiangya Hospital, Central South University, 139 Renmin Road, Changsha, 410011, Hunan, People's Republic of China.
Health Management Center, The 2nd Xiangya Hospital, Central South University, 139 Renmin Road, Changsha, 410011, Hunan, People's Republic of China.
Hunan Provincial Key Laboratory of Metabolic Bone Diseases, The 2nd Xiangya Hospital, Central South University, 139 Renmin Road, Changsha, 410011, Hunan, People's Republic of China.

H Liu (H)

Department of Metabolism and Endocrinology, The Affiliated Zhuzhou Hospital Of XiangYa School Of Medicine, Central South University, Changjiang South Road116, Zhuzhou, 412007, Hunan, People's Republic of China.

Z Xie (Z)

Department of Metabolism and Endocrinology, The 2nd Xiangya Hospital, Central South University, 139 Renmin Road, Changsha, 410011, Hunan, People's Republic of China.
National Clinical Research Center for Metabolic Diseases, The 2nd Xiangya Hospital, Central South University, 139 Renmin Road, Changsha, 410011, Hunan, People's Republic of China.
Hunan Provincial Key Laboratory of Metabolic Bone Diseases, The 2nd Xiangya Hospital, Central South University, 139 Renmin Road, Changsha, 410011, Hunan, People's Republic of China.

Y Ou (Y)

Hospital Infection Control Center, The 2nd Xiangya Hospital, Central South University, 139 Renmin Road, Changsha, 410011, Hunan, People's Republic of China.

Z Sheng (Z)

Department of Metabolism and Endocrinology, The 2nd Xiangya Hospital, Central South University, 139 Renmin Road, Changsha, 410011, Hunan, People's Republic of China. shengzhifeng@csu.edu.cn.
National Clinical Research Center for Metabolic Diseases, The 2nd Xiangya Hospital, Central South University, 139 Renmin Road, Changsha, 410011, Hunan, People's Republic of China. shengzhifeng@csu.edu.cn.
Health Management Center, The 2nd Xiangya Hospital, Central South University, 139 Renmin Road, Changsha, 410011, Hunan, People's Republic of China. shengzhifeng@csu.edu.cn.
Hunan Provincial Key Laboratory of Metabolic Bone Diseases, The 2nd Xiangya Hospital, Central South University, 139 Renmin Road, Changsha, 410011, Hunan, People's Republic of China. shengzhifeng@csu.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH